You are here



Merck announced that the primary endpoint of noninferiority for the composite cardiovascular endpoint had been met in a study that evaluated sitagliptin, an oral dipeptidyl peptidase-4 inhibitor.


Recent Headlines

Meta-analysis hints at survival benefit with PCSK9 inhibitors

A meta-analysis of 24 clinical trials on monoclonal antibody treatments for hypercholesterolemia pointed to significant reductions in death and MIs, a finding that likely will catch the eye of the FDA as it considers approval for these new drugs. The results were published online April 28 in the Annals of Internal Medicine.

Cholesterol takes back seat to whole diet in USDA recommendations

It’s all about the whole diet, say experts in a draft of scientific findings on the U.S. Food and Drug Administration (USDA) website. The results, published for comment through April 8, offer diets for physicians to consider with their patients when working to improve cardiovascular risks, heart disease, obesity, and other health concerns.

Heart month: Well intentioned, but …

Valentine’s Day promotion starts in December. The push for heart care should be never ending.

Patients may be willing to take pills for longer lives, healthier outcomes

Daily pill taking is worth years of cardiovascular health to patients, according to a study published Feb. 3 in Circulation: Cardiovascular Quality and Outcomes. The study looked at the utility of taking cardiovascular prevention medicine by asking patients how much shorter they were willing to live, how much more they were willing to pay and what risk of death they were willing to have to avoid taking medications.

Cardiologist to fellow docs: Flu shots benefit heart, too

Flu season has returned and with it, a new round of vaccines. While this year the vaccine may not be a perfect match to the A strain, cardiologists will want to recommend the shot for their patients, regardless.

ACEIs but not ARBs may lower cardiac risk in diabetics

ACE inhibitors (ACEIs) may warrant consideration as a first-line therapy to prevent death and cardiovascular events in patients with diabetes mellitus, according to a meta-analysis published online March 31 in JAMA Internal Medicine. The analysis found lower rates of mortality and cardiovascular events with ACEIs, but no similar effects with ARBs.

ACC.14: STAMPEDE gallops forward with promising results at 3 years

Combining bariatric surgery with medical therapy for three years was more effective at glycemic control than medical therapy alone among obese patients with type 2 diabetes, according to research presented March 31 at the American College of Cardiology (ACC) scientific session in Washington, D.C.

ACC.14: Cardiovascular disease guidelines may not be best risk estimators
Differences between cardiovascular disease prevention guidelines mean that different proportions of individuals would be eligible for statin therapy, according to results presented March 29 at the American College of Cardiology (ACC) scientific session in Washington, D.C.
Talking statins

I heard on my car radio that 12.8 million more Americans would receive statins under new cholesterol guidelines. Well, they got the number right.

Guidelines swell ranks for statins by almost 13 million

Almost 13 million Americans between 40 and 75 years old would become eligible for statin therapy under new cholesterol guidelines, according to a study published online March 19 in the New England Journal of Medicine.